Found: 6
Select item for more details and to access through your institution.
Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 10, p. 2284, doi. 10.1111/dom.13807
- By:
- Publication type:
- Article
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1445, doi. 10.1111/dom.13679
- By:
- Publication type:
- Article
Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2408, doi. 10.1111/dom.13394
- By:
- Publication type:
- Article
Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study.
- Published in:
- Journal of Diabetes Investigation, 2020, v. 11, n. 3, p. 662, doi. 10.1111/jdi.13181
- By:
- Publication type:
- Article
Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 4, p. 1549, doi. 10.1007/s13300-018-0455-8
- By:
- Publication type:
- Article
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
- Published in:
- Endocrine Journal, 2018, v. 65, n. 7, p. 693, doi. 10.1507/endocrj.ej17-0491
- By:
- Publication type:
- Article